##  [Partnering opportunities - Platforms and AI](/node/600101 "Partnering opportunities - Platforms and AI") 

  



We are looking for innovative approaches to accelerate the development of therapeutics:



 Chemistry



  

- Artificial intelligence/Machine learning (AI/ML) approaches to accelerate discovery and synthesis of new molecular entities
- Automated synthesis and profiling platforms
- Novel cyclic peptide screening platforms

 ![Avi Spier](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/avi-spier.jpg.webp?itok=ILSvAUTj "Avi Spier")

 



#### Avi Spier

[Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission)









 

 

 



 



 Biotherapeutics



  

- Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery.
- Targeted delivery and selective tropism to key tissues/cell types
- Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates

 ![Gianfranco de Pascale](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/gianfranco-de-pascale.jpg.webp?itok=RG_Q7DsE "Gianfranco de Pascale")

 



#### Gianfranco de Pascale

[Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission)









 

 

 



 



 Cell and gene therapy



  

- Novel T-cell-based therapy approaches
- Approaches to reduce AAV immunogenicity
- NextGen gene editing (non-viral)
- Novel approaches for selective gene expression in target cells for GTx

 ![Markus Werner](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/markus-werne.jpg.webp?itok=QFdRZ5O7 "Markus Werner")

 



#### Markus Werner (Oncology)

[Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission)







 ![Elizabeth Leshen](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/ellizabeth-leshen.JPG.webp?itok=1bFitdPb "Elizabeth Leshen")

 



#### Elizabeth Leshen (Rare diseases and neuroscience)

[Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission)









 

 

 



 



 xRNA



  

- Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types
- Innovative siRNA chemistry platforms
- In vivo/In vitro platforms to identify and validate siRNA targets

 ![Gianfranco de Pascale](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/gianfranco-de-pascale.jpg.webp?itok=RG_Q7DsE "Gianfranco de Pascale")

 



#### Gianfranco de Pascale

[Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission)









 

 

 



 



 Radioligand therapy



  

- Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery
- Explore various combination approaches which are synergistic with RLTs
- Technologies to expand the therapeutic window of RLTs

 ![Shona Whyte portrait](/sites/novartis_com/files/styles/crop_freeform/public/2026-01/shona-whyte.jpg.webp?itok=1082kuf8 "shona-whyte")

 



#### Shona Whyte

[Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission)









 

 

 



 



 Artificial intelligence | Machine learning | Digital



  

We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:

- Enable deeper understanding of disease to identify novel therapeutic Targets
- Power small and large molecule design and optimization
- Increase predictive safety
- Improve trial design and execution

 ![Cynthia Hong](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/cindy-hong.jpg.webp?itok=OI5r4slc "Cynthia Hong")

 



#### Cynthia Hong

[Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission)









 

 

 



 



 

 





 



- [Print](/node/600101/printable/print)
- [PDF](/node/600101/printable/pdf)